Antibody Engineering for Pursuing a Healthier Future

Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua

Hybridoma technology has been a significant and essential platform for producing high-quality mAbs (Zhang, 2012) . It permits generation of therapeutic antibodies in a native form. However, technical difficulties in hybridoma production have updated the mainstream antibody production into new ways like display and transgenic mice techniques. Nevertheless, hybridoma technology is a classical and established route of generating specific antibodies all around the globe (Glukhova et al., 2016) . The technology begins with immunization of test animals with an antigen of interest and serum antibody titer is determined by enzyme linked immunosorbent assay (ELISA). Subsequently, the spleen is aseptically removed and splenocytes are fused with myeloma cells to produce hybridoma cells. Hybridoma cells are then cultured in 96-well plates in the presence of hypoxanthine-aminopterin-thymidine (HAT) selection medium for high throughput screening. Later, hybridoma cells producing desired antibodies are screened by conventional ELISA and novel nanoparticle-probed immunoassay (colloidal gold or silver nanoparticles; Figure 2 ). Cell culture systems in vitro with specific mAb cell lines were then subjected to mass generation by media selection, shaker flasks, and bench-scale bioreactors .